Pruritus associated with intravenous rifampin.
OBJECTIVE
To report a probable case of moderate pruritus associated with intravenous rifampin.


METHODS
A 57-year-old woman was started on vancomycin 1 g i.v. q72h following a positive blood culture for methicillin-resistant Staphylococcus epidermidis. The patient's past medical history was significant for uterine carcinoma, radiation-induced enteritis, congestive heart failure, and renal insufficiency. Other therapy consisted of total parenteral nutrition, digoxin 0.125 mg/d i.v., and furosemide 60 mg i.v. prn for edema. Seven days later, the patient's white blood cell count increased and rifampin 600 mg/d i.v. was added to the drug regimen for potential synergy. On day 3 of rifampin therapy, the patient experienced pruritus beginning 30 minutes after the rifampin infusion ended and lasting for 6-8 hours. After 7 days of rifampin therapy, the medication was discontinued and the pruritus resolved.


CONCLUSIONS
This case evaluation demonstrated probable pruritus induced by intravenous rifampin. Clinicians should be alerted that intravenous rifampin, as well as orally administered rifampin, has the potential to cause moderate pruritus.
Walker-Renard
P
P
Pharmacy Corporation of America, Kennewick, WA 99336, USA.
D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D011537:Pruritus / Q000139:chemically induced*; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D014640:Vancomycin / Q000627:therapeutic use
D014640:Vancomycin; D012293:Rifampin